Eupraxia Pharmaceuticals Inc.: Form 40-F for the period ended Dec 31, 2023
Filed with the SEC on Apr 1, 2024 and accepted by EDGAR at Apr 1, 2024, 21:11 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2023-01-01 to 2023-12-31 | $0 | us-gaap:Revenues |
| Research and development | 12 months2023-01-01 to 2023-12-31 | $20.6m | us-gaap:ResearchAndDevelopmentExpense |
| Interest expense | 12 months2023-01-01 to 2023-12-31 | $1.2m | us-gaap:InterestExpense |
| Income tax | 12 months2023-01-01 to 2023-12-31 | $36.4k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2023-01-01 to 2023-12-31 | −$28.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2023-01-01 to 2023-12-31 | −$1.17 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2023-01-01 to 2023-12-31 | −$1.17 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2023-01-01 to 2023-12-31 | 24,146,623 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2023-01-01 to 2023-12-31 | −$20.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2023-12-31 | $19.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-12-31 | $19.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-12-31 | $20.3m | us-gaap:Assets |
| Current liabilities | At period end2023-12-31 | $19.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-12-31 | $19.4m | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-12-31 | $2.2m | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2023-12-31 | 27,282,165 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001193125-24-083584. Last ingested by Listed: Oct 24, 2026, 15:14 ET. Listed shows no prices and gives no investment advice.